BerGenBio ASA Registered Shs Aktie [WKN DE: A2DPC0 / ISIN: NO0010650013]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu BerGenBio ASA Registered Shs

09.12.19		BerGenBio Presents Preliminary Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC in Elderly AML Patients at ASH 2019 (PR Newswire)
09.12.19		BerGenBio Presents Preliminary Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC in Elderly AML Patients at ASH 2019 (PR Newswire)
19.11.19		BerGenBio ASA: Results for the Third Quarter 2019 (PR Newswire)
19.11.19		BerGenBio ASA: Results for the Third Quarter 2019 (PR Newswire)
08.11.19		BerGenBio Presents Updated Phase 2 NSCLC Clinical and Translational Data for Bemcentinib in Combination With KEYTRUDA® (PR Newswire)
07.11.19		BerGenBio to Present Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC Trial in Elderly AML Patients at ASH 2019 (PR Newswire)
07.11.19		BerGenBio to Present Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC Trial in Elderly AML Patients at ASH 2019 (PR Newswire)
07.11.19		BerGenBio ASA: Invitation to Third Quarter 2019 Results Presentation and Webcast (PR Newswire)
07.11.19		BerGenBio ASA: Invitation to Third Quarter 2019 Results Presentation and Webcast (PR Newswire)
06.11.19		BerGenbio's Bemcentinib Meets Primary Endpoint in First Cohort of Phase 2 NSCLC Study in Combination With Keytruda® (PR Newswire)
06.11.19		BerGenbio's Bemcentinib Meets Primary Endpoint in First Cohort of Phase 2 NSCLC Study in Combination With Keytruda® (PR Newswire)
22.10.19		BerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib (PR Newswire)
22.10.19		BerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib (PR Newswire)
02.10.19		BerGenBio to Present Clinical Data From Phase II Trial With Selective AXL Inhibitor at 34th Annual SITC Meeting (PR Newswire)
02.10.19		BerGenBio to Present Clinical Data From Phase II Trial With Selective AXL Inhibitor at 34th Annual SITC Meeting (PR Newswire)
27.09.19		BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib at the European Society for Medical Oncology (ESMO) 2019 Congress (PR Newswire)
27.09.19		BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib at the European Society for Medical Oncology (ESMO) 2019 Congress (PR Newswire)
09.09.19		BerGenBio Presents Phase II Trial Updates With Selective AXL Inhibitor Bemcentinib in Non-Small Cell Lung Cancer at 2019 World Conference on Lung Cancer (PR Newswire)
19.08.19		BerGenBio ASA: Results for the Second Quarter and First Half 2019 (PR Newswire)
19.08.19		BerGenBio ASA: Results for the Second Quarter and First Half 2019 (PR Newswire)
14.06.19		BerGenBio Presents Preliminary Phase II Clinical Data at EHA 24: Bemcentinib in Combination With Low Dose Chemotherapy Yields Durable Responses in AML Patients Unfit for Intensive Chemotherapy (PR Newswire)
14.06.19		BerGenBio Presents Preliminary Phase II Clinical Data at EHA 24: Bemcentinib in Combination With Low Dose Chemotherapy Yields Durable Responses in AML Patients Unfit for Intensive Chemotherapy (PR Newswire)
03.06.19		BerGenBio Presents New Phase II Clinical Data That Bemcentinib in Combination With Low Dose Chemotherapy Improves Efficacy and Duration of Survival in Elderly AML Patients at ASCO 2019 (PR Newswire)
02.06.19		BerGenBio Presents New Preliminary Clinical and Biomarker Data Showing Durable Response & Median Survival Rates in Phase II Trial With Bemcentinib and KEYTRUDA in Pts With Advanced NSCLC at ASCO 2019 (PR Newswire)
02.06.19		BerGenBio Presents New Preliminary Clinical and Biomarker Data Showing Durable Response & Median Survival Rates in Phase II Trial With Bemcentinib and KEYTRUDA in Pts With Advanced NSCLC at ASCO 2019 (PR Newswire)
16.05.19		BerGenBio to Present New NSCLC and AML Clinical Data and Biomarker Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019 (PR Newswire)
16.05.19		BerGenBio to Present New NSCLC and AML Clinical Data and Biomarker Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019 (PR Newswire)
08.05.19		BerGenBio Completes Recruitment Into Second Stage of Phase II Trial With Selective AXL inhibitor bemcentinib in Combination with KEYTRUDA® in Patients With Advanced NSCLC (PR Newswire)
08.05.19		BerGenBio Completes Recruitment Into Second Stage of Phase II Trial With Selective AXL inhibitor bemcentinib in Combination with KEYTRUDA® in Patients With Advanced NSCLC (PR Newswire)
08.05.19		BerGenBio ASA: Results for the First Quarter 2019 (PR Newswire)
08.05.19		BerGenBio ASA: Results for the First Quarter 2019 (PR Newswire)
24.04.19		BerGenBio ASA: Invitation to First Quarter Presentation and Webcast (PR Newswire)
24.04.19		BerGenBio ASA: Invitation to First Quarter Presentation and Webcast (PR Newswire)
23.04.19		BerGenBio to Present NSCLC and AML Clinical Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019 (PR Newswire)
23.04.19		BerGenBio to Present NSCLC and AML Clinical Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019 (PR Newswire)
09.04.19		BerGenBio to Present at H.C. Wainwright Global Life Sciences Conference (PR Newswire)
09.04.19		BerGenBio to Present at H.C. Wainwright Global Life Sciences Conference (PR Newswire)
02.04.19		BerGenBio Extends Phase II Trial With Bemcentinib and KEYTRUDA® in NSCLC to Include Patients With Disease Progression on Immune Checkpoint Inhibitor Therapy (PR Newswire)
02.04.19		BerGenBio Extends Phase II Trial With Bemcentinib and KEYTRUDA® in NSCLC to Include Patients With Disease Progression on Immune Checkpoint Inhibitor Therapy (PR Newswire)
01.04.19		BerGenBio: Bemcentinib in Combination With low-dose Chemotherapy Achieves Efficacy Endpoint in AML Patients (PR Newswire)
01.04.19		BerGenBio: Bemcentinib in Combination With low-dose Chemotherapy Achieves Efficacy Endpoint in AML Patients (PR Newswire)
20.02.19		BerGenBio ASA Publishes Annual Report for 2018 (PR Newswire)
20.02.19		BerGenBio ASA Publishes Annual Report for 2018 (PR Newswire)
12.02.19		BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018 (PR Newswire)
12.02.19		BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018 (PR Newswire)
21.01.19		BerGenBio Announces Start of Phase I Trial Evaluating ADCT-601, a Novel Anti-AXL ADC, in Patients With Advanced Solid Tumours (PR Newswire)
21.01.19		BerGenBio Announces Start of Phase I Trial Evaluating ADCT-601, a Novel Anti-AXL ADC, in Patients With Advanced Solid Tumours (PR Newswire)
09.01.19		BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL Antibody BGB149 (PR Newswire)
09.01.19		BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL Antibody BGB149 (PR Newswire)
04.01.19		BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in High-risk MDS (PR Newswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Neuer Rekord nicht mehr weit: Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse am Mittag entwickeln

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

Nah an 100.000er Marke: Bitcoin, Dogecoin, Ethereum & Co. am Vormittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.11.2024 18:29
Kaufwert:	EUR
	Hinzufügen Speichern